Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: A phase I-II trial

British Journal of Cancer

Volumn 93, Issue 10, 2005, Pages 1106-1111

  Stathopoulos, G P ^a,e   Dimitroulis, J ^b   Antoniou, D ^b   Katis, C ^c   Tsavdaridis, D ^d   Armenaki, O ^b   Marosis, C ^b   Michalopoulou, P ^b   Grigoratou, T ^b   Stathopoulos, J ^a  

^a Errikos Dunant Hospital   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c THRIASIO GENERAL HOSPITAL   (Greece)

^d IKA Hospital   (Greece)

^e IKA Hospital ^*  (Greece)

Author keywords

Irinotecan; Non small cell lung cancer; Paclitaxel

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; IRINOTECAN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL RATE;

EID: 27944468737     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602827     Document Type: Article

References (38)

1. Adjei AA, Klein CE, Kastrissios H, Goldberg RM, Alberts SR, Pitot HC, Sloan JA, Reid JM, Hanson LJ, Atherton P, Rubin J, Erlichman C (2000) Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 18: 1116-1123
2. Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels E (1997) Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol 24(Suppl 12): S12-S13
3. Belani CP, Keams CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ (1999) Phase I trial including pharmacokinetic and pharmacodynamic correlations of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17: 676-684
4. Bonomi P, Kim KM, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients with dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631
5. Cardenal F, Domine M, Massuti B, Carrato A, Felip E, Carrido P, Juan D, Artal A, Barneto I, Lopez-Vivenco G, Balcells M, Rosell R (2003) Three week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 39: 201-207
6. Chang AY, de Vore R, Johnson D (1996) Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 23: S19-S21
7. Chou T-C, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantiation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524
8. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C, Tonato M (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15: 297-303
9. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrava G, Gozzelino F, Tonato M (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530
10. Douillard J, Cunningham D, Roth A, Navarro M, James RD, Karasek P, Jandik P, Ireson T, Carmichael J, Alaki M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355: 1041-1047
11. Fossella F, De Vore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammers-haimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-2362
12. Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, De Cataldis G, Belli M, Micillo E, Mascia V, Massidda B, Loruso V, De Lena M, Carpagnano F, Contu A, Pusceddu G, Comella G (1999) Cisplatin, gemcitabine and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. J Clin Oncol 17: 2316-2325
13. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas Ph, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet 357: 1478-1484
14. Giaccone G, Splinter TAW, Debruyne Ch, Knot GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus PE (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 16: 2133-2141
15. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30
16. Greco A, Hainsworth JD (1997) Paclitaxel (1-h infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Semin Oncol 24: S12-S14
17. Hotta K, Usoka H, Kiura K, Tabata M, Kuyama S, Satoli K, Kozuki T, Hisamoto A, Hosokawa S, Fujiwara K, Tanimoto M (2004) A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small-cell lung cancer. Lung Cancer 45: 77-84
18. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DE Vore III RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing beracizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191
19. Kakolyris S, Kouroussis Ch, Souglakos J, Agelaki S, Kalpakis K, Vardakis N, Vamvakas L, Georgoulias V (2001) Cisplatin and irinotecan (CPT-11) as a second-line treatment in patients with advanced non-small-cell lung cancer. Lung Cancer 34: s71-s76
20. Kakolyris S, Souglakos J, Agelaki S, Kourousis Ch, Mavroudis D, Sarra E, Malliotakis P, Georgoulias V (2000) A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small-cell lung cancer previously treated with a docetaxel-based front line chemotherapy. Lung Cancer 30: 193-198
21. Kasai T, Oka M, Soda H, Tsuvutani J, Fukuda M, Nakamura Y, Kawabata S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Kinoshita A, Kohno S (2002) Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small-cell lung cancer. Eur J Cancer 38: 1871-1878
22. Kaufmann SH, Peeveboom D, Buckwalter CA, Sringen PA, Grochow LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734-741
23. Keresztes RS, Socinski M, Bonomi P, Chen A, Hart L, Lilenbaum R (2004) Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC). ASCO Proceedings Vol. 23. New York, N.Y.: Cornell University
24. Kouroussis Ch, Androulakis N, Kakolyris S, Souglakos J, Maltezakis G, Metaxaris G, Chalkiadakis G, Samonis G, Vlachonikolis J, Georgoulias V (1998) First line treatment of advanced non-small-cell lung carcinoma with docetaxel and vinorelbine. Cancer 83: 2083-2090
25. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367
26. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M (2003) Randomized Phase III Trial of irinotecan combined with cisplatin for advanced non-small cell lung cancer. Br J Cancer 10(88/3): 335-341
27. Ohyanagi F, Nishio M, Horai T, Kasahara K, Shibata K, Takeda Y (2004) A phase II trial of gemcitabine and irinotecan in patients with refractory or relapsednon-small-cell lung cancer. ASCO Proceedings Vol. 23. Tokyo, Japan: Cancer Institute Hospital
28. Rocha-Lima C-MS, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Sarille W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR (2002) Irinotecan plus gemcitabine induces both radiographic and CA-19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20: 1182-1191
29. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J (1999) Multitargeted antifolate LY 231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer. A phase II study - National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17: 1194-1199
30. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914
31. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL, Ledermann JA, Leonard P, Seymour M, Miller LL (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345: 144-145
32. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E (2001) Phase II study of premetrexed disodium, a multitargeted antifolate and cisplatin first-line therapy in patients with advanced non-small-cell lung carcinoma. Cancer 92: 595-600
33. Socinski MA, Sandler AB, Israel VK, Gillenwater HH, Miller LL, Locker PK, Antonellini A, Elfring GL, Natale RB (2002) Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated stage IIIb/IV non-small-cell lung carcinoma. Cancer 95: 1520-1527
34. Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB (2001) Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 19: 1078-1087
35. Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG, Georgoulias V (2003) Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 14: 388-394
36. Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K, Tsavdaridis D, Rigatos SK, Dimitroulis I, Bastani S, Loukides S, Vergos K, Marossis K, Grigoratou T, Kalatzi E, Charalambatou M, Paspalli A, Michalopoulou P, Stoka M, Gerogianni A (2004) Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 15: 1048-1055
37. Wasserman E, Cuvier C, Lokiec F, Goldivasser F, Kalla S, Mery-Mignard D, Ouldkaci M, Besmaine A, Dupont-Andre G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E (1999) Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 17: 1751-1759
38. Yamada K, Ikehara M, Tanaka G, Nomura I, Oshita F, Noda K (2004) Dose escalation study of paclitaxel in combination with fixed-dose irinotecan in patients with advanced non-small-cell lung cancer (JCOG 9807). Oncology 66(2): 94-100